Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Salarius expands oncology drug pipeline with DeuteRx portfolio acquisition By: Houston Business Journal via Business Journals January 14, 2022 at 13:52 PM EST The deal "provides entry into the exciting field of protein degradation, a fast-growing area of cancer drug research that is attracting substantial interest from some of the world’s largest pharmaceutical companies because of the potential advantages of protein degraders, including the ability to go after previously undruggable cancer-promoting targets," said David Arthur, CEO of Salarius. Read More >> Related Stocks: Harbor Disruptive Innovation ETF Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
Salarius expands oncology drug pipeline with DeuteRx portfolio acquisition By: Houston Business Journal via Business Journals January 14, 2022 at 13:52 PM EST The deal "provides entry into the exciting field of protein degradation, a fast-growing area of cancer drug research that is attracting substantial interest from some of the world’s largest pharmaceutical companies because of the potential advantages of protein degraders, including the ability to go after previously undruggable cancer-promoting targets," said David Arthur, CEO of Salarius. Read More >> Related Stocks: Harbor Disruptive Innovation ETF